Superior Semicircular Canal DehiscenceSDCS-PSYNCT07922447
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
An observational study of Superior Semicircular Canal Dehiscence, run by University Hospital, Toulouse.
Trial summary
Superior semicircular canal dehiscence syndrome (SSCD), also known as Minor syndrome, is a rare otoneurological condition characterized by auditory and vestibular symptoms. Emerging evidence suggests a significant psychological burden, including anxiety, depressive symptoms, and suicidal ideation, potentially related… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Superior Semicircular Canal Dehiscence
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- Nov 2026to Nov 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient selection was based on internal communication to members by the French association of patients with Mineur syndrome. The study was disseminated through specialized consultations.
Who may be able to join
- Age ≥ 18 years
- Self-reported diagnosis of superior semicircular canal dehiscence syndrome
- Ability to understand French
- Non-opposition to participation
Who cannot join
- Refusal of data use for research purposes
- Self-reported cognitive impairment preventing questionnaire completion
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Superior semicircular canal dehiscence syndrome (SSCD), also known as Minor syndrome, is a rare otoneurological condition characterized by auditory and vestibular symptoms. Emerging evidence suggests a significant psychological burden, including anxiety, depressive symptoms, and suicidal ideation, potentially related to diagnostic delay and chronic symptomatology. However, no structured epidemiological study has systematically assessed quality of life and psychological symptoms in this population.
The aim of this study is to evaluate quality of life and associated psychological symptoms in adults reporting a diagnosis of SSCD using validated self-reported questionnaires in a national cross-sectional survey.
- Conditions
- Superior Semicircular Canal Dehiscence
- Keywords
- Superior semicircular canal dehiscence, Minor syndrome, quality of life, anxiety, depression, rare disease, otoneurology
- Medical subject headings
- Semicircular Canal Dehiscence, Anxiety Disorders, Depression, Rare Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| patients with superior semicircular canal dehiscence syndrome | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall quality of life score measured using the WHOQOL-BREF questionnaire
Measured: The inclusion day
Secondary outcomes (6)
Assessment of the prevalence of depressive symptoms in patients living with CSDS using the average score found on the Beck Depression Inventory (BDI) scale
Measured: The inclusion day
Assessment of the prevalence of anxiety symptoms in patients living with CSDS using the mean score found on the State-Trait Anxiety Inventory (STAI-Y)
Measured: The inclusion day
Assessment of the symptomatic intensity level of each symptom of the SDCS using an average score per item and an overall average score on the Naert questionnaire
Measured: The inclusion day
Assessment of the impact of vestibular symptoms on the functioning of patients living with CSDS using the average score found on the Dizziness Handicap Inventory (DIH) scale
Measured: The inclusion day
Assessment of the level of hopelessness in patients living with SDCS using the average score found on the Beck Hopelessness Scale (BHS)
Measured: The inclusion day
To assess the difference in quality of life between adult patients who underwent surgical management of their CSSD and others using the WHOQOL-BREF score
Measured: The inclusion day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2028 (estimated)
- Study completionNov 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Superior Semicircular Canal DehiscenceStudies of the same condition, open and under way.
- More trials run by University Hospital, ToulouseThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Toulouse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07922447
- Sponsor's protocol ID
- RC31/26/0193
- Acronym
- SDCS-PSY
- Status last verified
- Nov 2026
- First submitted
- 2 Nov 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
- ClinicalTrials.gov ID
- NCT07922447
- Acronym / sponsor ID
- SDCS-PSY / RC31/26/0193
- Conditions
- Superior Semicircular Canal Dehiscence
- Keywords
- Superior semicircular canal dehiscence, Minor syndrome, quality of life, anxiety, depression, rare disease, otoneurology
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University Hospital, ToulouseUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Nov 2028 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Superior semicircular canal dehiscence syndrome (SSCD), also known as Minor syndrome, is a rare otoneurological condition characterized by auditory and vestibular symptoms. Emerging evidence suggests a significant psychological burden, including anxiety, depressive symptoms, and suicidal ideation, potentially related to diagnostic delay and chronic symptomatology. However, no structured epidemiological study has systematically assessed quality of life and psychological symptoms in this population.
The aim of this study is to evaluate quality of life and associated psychological symptoms in adults reporting a diagnosis of SSCD using validated self-reported questionnaires in a national cross-sectional survey.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with superior semicircular canal dehiscence syndrome | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient selection was based on internal communication to members by the French association of patients with Mineur syndrome. The study was disseminated through specialized consultations.
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- Self-reported diagnosis of superior semicircular canal dehiscence syndrome
- Ability to understand French
- Non-opposition to participation
Key exclusion criteria (2 listed)
- Refusal of data use for research purposes
- Self-reported cognitive impairment preventing questionnaire completion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall quality of life score measured using the WHOQOL-BREF questionnaire
Time frame: The inclusion day
6 secondary outcomes
Assessment of the prevalence of depressive symptoms in patients living with CSDS using the average score found on the Beck Depression Inventory (BDI) scale
Time frame: The inclusion day
Assessment of the prevalence of anxiety symptoms in patients living with CSDS using the mean score found on the State-Trait Anxiety Inventory (STAI-Y)
Time frame: The inclusion day
Assessment of the symptomatic intensity level of each symptom of the SDCS using an average score per item and an overall average score on the Naert questionnaire
Time frame: The inclusion day
Assessment of the impact of vestibular symptoms on the functioning of patients living with CSDS using the average score found on the Dizziness Handicap Inventory (DIH) scale
Time frame: The inclusion day
Assessment of the level of hopelessness in patients living with SDCS using the average score found on the Beck Hopelessness Scale (BHS)
Time frame: The inclusion day
To assess the difference in quality of life between adult patients who underwent surgical management of their CSSD and others using the WHOQOL-BREF score
Time frame: The inclusion day
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Superior Semicircular Canal Dehiscence
Not yet recruiting
The Diagnostic Accuracy of Ankle Audiometry Performed With the B250 for Superior Canal Dehiscence Syndrome in Patients Affected by Pulsatile Tinnitus and/or Autophony Disorders
Superior Canal Dehiscence Syndrome, Autophony
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Superior Semicircular Canal Dehiscence, run by University Hospital, Toulouse.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Valentin RAYMOND, Dr (+33 5.61.77.73.15, raymond.v@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall quality of life score measured using the WHOQOL-BREF questionnaire (time frame: The inclusion day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.